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Abstract:
Chronic Traumatic Encephalopathy (CTE) is a neuropathological disease that develops
years after experiencing repetitive traumatic brain injuries. In recent years, this disease has
been gaining recognition from professional, college, and high school teams that participate in
contact sports. The purpose of this paper is to review available information about this
neurodegenerative disease. Only limited published experiments are available on this disease.
Research on CTE has been limited by the fact that patients can only be diagnosed with the
disease by a post mortem autopsy. Many experiments were analyzed regarding different CTE
pathologies, symptoms, and treatments. Articles used in this paper were restricted to only peer
reviewed pieces. The outcome resulted in credible information about the disease, its
neuropathy, and signs and symptoms, as well as possible treatment methods of the disease.

3

Main Text:
On July 25th, 2017 the New York Times published data from a study that stated 110 out
of 111 former NFL players had been discovered to have Chronic Traumatic Encephalopathy.
Chronic Traumatic Encephalopathy, or CTE, is a neurodegenerative disease that has been linked
to repetitive, mild traumatic brain injuries. CTE has been associated with a variety of symptoms,
some of them being depression, memory loss, and aggression. Signs and symptoms do not
appear until years after the initial injury and the disease is very progressive in later years.
Understanding CTE first takes an understanding of a traumatic brain injury. A traumatic brain
injury (TBI) is a significant blow or jolt to the head that can cause altered brain function or
feeling. An example of a mild traumatic brain injury is a concussion. Concussions are a common
head injury among participants in contact sports or of those who serve in the military.
According to the University of Pittsburgh’s Brain Trauma Research Center, there are 300,000
sports-related concussions that occur annually in the U.S. Furthermore, the probability of a
participant experiencing a concussion per season is as high as 19% (1). This paper will discuss
and review findings that relate these mild traumatic brain injuries (mTBI) and the pathogenesis
of CTE.
CTE hasn’t always been highly acknowledged in past years. It was initially recognized by
Dr. Martland in boxers who suffered from similar symptoms of being classified as “Punch
Drunk” (5). Dr. Martland had a career as a medical examiner, forensic pathologist, and teacher
in New Jersey and New York (24). Later, Dr. Millspaugh, a naval medical officer, introduced the
term “dementia pugilistica,” in 1937, to describe these same symptoms (6). It wasn’t until 1949,
however, that the term “chronic traumatic encephalopathy” was suggested by Dr. Critchley,
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world renowned neurologist, and then changed to “chronic progressive traumatic
encephalopathy of boxers” in 1957 (13,14,15). These sub-concussive hits being suffered by
boxers were soon recognized in other contact sport participants and serving military members.
All of these sports or activities could result in collisions or concussive blows to the skull that
would possibly result in a mild traumatic brain injury (mTBI).
Clinical Presentation:
Previously, brain injuries could only be diagnosed by the patients’ symptom description,
which presented 8-10 years after experiencing the mTBI. Symptoms of CTE can include
headaches, rapid mood swings, impulsive aggression, increased irritability, aggression, memory
loss, varying levels of depression, and, in some cases, gait abnormalities. One of the most
severe symptoms can be suicidal thoughts and actions (16).
Diagnosing and researching a brain disease or injury such as CTE was historically difficult
to do because the only way to see the brain was post mortem. Although the histological
techniques varied, the most common pathological findings were cerebral atrophy, neuronal
loss, gliosis and argyrophilic neurofibrillary tangles (2). Fortunately, the way we view the brain
and possible brain injuries has advanced dramatically over recent years. X-Rays, CT scans, and
MRI’s are now used to take images of the brain, and PET scans can even show functions of the
brain.
Pathogenesis:
Tau:

Tau is an abundant protein found in neurons that associates with the stabilization of

microtubules and axonal transport (Figure 1) (29). In CTE, specifically, it presents itself in
abundance in a unique pattern of neurofibrillary tangles, classified as a taupathy. A taupathy is
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any neurodegenerative disorder characterized by abnormally hyper-phosphorylated tau that
has misfolded into insoluble aggregates known as neurofibrillary tangles (NFT) (29,2,22). Some
examples of common taupathies are progressive supranuclear palsy (PSP), corticobasal
degeneration (CBD), Pick’s disease, and frontotemporal dementias with parkinsonism and
Alzheimer’s disease (22).

Figure 1: A brain cell or neuron. The axon of the cell is very long and thin, which makes it the
weakest point in the cell. Also it is easily damaged during this and can lead to trouble sending
signals in the brain (41).
Once hyper-phosphorylated, tau assumes a tightly folded confirmation this causes an
increase in susceptibility to aggregation, conformational change, filament assembly,
polymerization into paired helical filaments, and bundling of paired helical filaments into
neurofibrillary tangles and neuropil threads (Figure 2) (17). Tau phosphorylation also leads to
decreased binding with microtubules and lowers overall microtubule stability. The
accumulation of tau within these neurons causes synaptic dysfunction and, eventually, cell
death (Gou). Studies have shown an association with mutations of the tau gene that lead to
dementia and parkinsonism, showing us that a dysfunction of tau proteins is sufficient to cause
neurodegeneration and dementia (30).
6

Figure 2: A small transport system within the cells is made up of microtubules. Tau protein
helps stabilize these small tubes in a normal healthy brain. In CTE, tau proteins begin clumping
to one another and block this transport system (41).
Even though all verified cases of CTE have been related to repetitive mTBI, the
mechanism of neurodegeneration and taupathy are not fully understood (2). Previous studies
have shown that rapid acceleration-deceleration injuries have been associated with generating
these neurotoxic tau fragments, but the development of deterioration has yet to be discovered
(2). Symptoms of CTE normally present themselves later in life, which may be due to the prionlike mechanism of p-tau. One theory behind CTE being progressive and is that p-tau can spread
and aggregate in other areas of the brain. This theory has been demonstrated in mouse models
by injecting areas of their brain with filamentous human Alzheimer’s disease linked taupathy
proteins and observing their propagation (30). The taupathies expanded from the injection site
to other distant brain regions connected by synapses. An additional study confirmed tau
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propagation using a silver staining technique to identify tau in neighboring brain regions of
hippocampal injected mice (30). The mechanism in which insoluble tau becomes seeded into
neighboring cells is absorptive endocytosis. This mechanism was demonstrated in a particular
study demonstrating the uptake of a preformed tau fibril by endocytosis recruits large amounts
of endogenous tau within the cell to form filamentous tau inclusions (31).
Lewy Bodies:
Lewy bodies are accumulations of the protein alpha-synuclein within neurons of the
brain (38). These accumulations have been associated with Parkinson’s disease, Alzheimer’s
disease, and Lewy body disease (18). CTE, being known as a comorbid disease, has spurred
researchers to begin studying these protein accumulations as a possible cofactor of the disease.
A recent study sought out a connection between Lewy bodies and CTE within individuals who
had suffered mTBI. In this study, researchers took a pool of 694 autopsy participants from 3
distinct brain donation groups and neuro-pathologically evaluated them for neurodegenerative
diseases (18). Out of the 694 donations, 269 of the participants were recruited from the
Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) study donation group
who had a history of some form of contact sport at the professional or amateur level. The other
groups were from the Boston University’s Alzheimer Disease Center (ADC) (261 participants),
and from a brain bank of the Farmingham Heart Study (FHS) (164 participants). In the UNITE
group, this study completed an extensive repeated head injury (RHI) and sports questionnaire
to understand the history of all the participants. The next of kin of the FHS group completed an
identical athletic history assessment. Participants’ exposure to RHI was defined by the total
number of years a contact sport was played or years of service in the military. Prior to death,
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the UNITE group participants’ mood, behavior, cognitive, and clinical statuses were evaluated
by online surveys (18).
The neuropathological diagnosis of CTE was made using the National Institute of
Neurological Disorders (NINDS) consensus criteria that is rated on a scale of I to IV based on
severity, described later in this paper. A diagnosis of Alzheimer’s diseases (AD) was made based
of the National Institute of Aging Reagan criteria, which included intermediate or high
probability. For a participant to be diagnosed with AD, they would have to have sufficient
pathology to be classified under the intermediate probability. Lewy bodies were assessed with
a-synuclein immunohistochemistry throughout the brain and rated on a scale of 0 to III. These
brain regions were viewed by 200x magnification and scored on the following: areas with no
Lewy bodies were scored 0, 1-2 Lewy bodies were scored “1,” 3-4 Lewy bodies were scored “2,”
and areas with 5 or more Lewy bodies were scored “3.”
Age is a known factor of neurodegenerative pathology and no participants under the
age of 50 years old were found to have Lewy bodies or AD. This required comparisons with the
CTE pathology groups to be done with participants who had died at an age older than 50 years
old. Comparisons were made into four groups based on distributions of the Lewy bodies
between the pathological subjects. The groups were LBD, CTE-LBD, AD-LBD, and CTE-AD-LBD.
Participants with CTE-LBD had higher deposition of Lewy bodies in the brainstem and lower
deposition in the amygdala-predominant compared to AD-LBD. Neocortical deposition of Lewy
bodies was 53% higher in CTE-AD-LBD than in the other groups followed by CTE-LBD. Also, Lewy
bodies for the CTE-LBD group were found higher in the limbic system compared to the other
groups with AD-LBD being the second highest (18).
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Table 1: Table showing measurements CTE, CTE-LBD, and CTE-AD-LBD groups comparatively
(18).
Key findings of this study were that individuals known to have CTE had an overall lower
average age of death. It also showed a substantial increase in dementia and parkinsonism’s
within patients when both CTE and LBD were observed compared to CTE alone. Dementia in
patients rose 30% from 61.4% (seen in CTE alone) to 91.4% when CTE and LBD were both
present. Only 19.5% of patients who were diagnosed with CTE alone had parkinsonism’s.
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Parkinsonism’s in patients who qualified as having both CTE and LBD jumped to 60% (Table 1).
Although these pools were not equal, there is an obvious association between Lewy bodies
being present and an increase of these symptoms. The study also showed that individuals who
had more years of exposure to contact sports were more likely to have neocortical Lewy body
accumulation. Those who had 8 or more years of exposure of contact sports were 6.24 times
more likely to be diagnosed with LBD compared to those with 7 or less years of exposure (18).
Anatomy:
Gross anatomical abnormalities have been observed during autopsies in individuals with
a pathology currently associated with CTE. These abnormalities are due to neuronal loss caused
by phosphorylated tau accumulation. Some of these abnormalities include: reduction of total
brain weight, enlargement of ventricles, atrophy of functional brain structures, cavum septum
pollicidum, and depigmentation of the locus coeruleus and substantia nigra (2). These
abnormalities differ between patients depending on when TBI’s occurred. To have proper
understanding of these abnormalities and possible symptomatic effects they may have on an
individual, one must first know the basic anatomy of the major parts of the brain affected by
CTE.
The first part, the cerebrum, consists of the right and left hemisphere, which work
together to control the body. Within each hemisphere are four lobes, named regionally: the
occipital, temporal, parietal, and frontal lobes. Each lobe hosts specific higher level brain
functions. The occipital lobes are responsible for processing vision and the temporal lobes
process memories and relate them to senses. The parietal lobes register temperature, touch,
and movement, whereas the frontal lobes control movement and cognitive function (Figure 3)
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(32, 33).

Figure 3: Regional lobes of the cerebrum and their overlying cortices. This figure shows the
cerebral lobes and cortex regions affected by CTE (32).
A major part of the cerebrum is the cerebral cortex. The cerebral cortex is the
outermost surface of the cerebral hemispheres and is known to be the location of where the
highest functions are carried out. The cerebral cortex consists of ridges, called gyri, and valleys,
called sulci, that add surface area to the cortex, which increases the amount of gray matter for
information storage. The cerebral cortex is divided into four regional areas that correspond to
the cerebrum; they possess specific functions such as learning, remembering, and language and
sensory processing (32, 33).
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Figure 4: The limbic system of the brain. This figure shows some of the limbic system
structures affected by CTE. The mammillary body, hippocampus, amygdala and thalamic region
(42).
Another major area of the brain affected by CTE is the limbic system. A few important
structures within the limbic system are the amygdala, thalamus, hippocampus, and mammillary
bodies. These structures are interconnected and control emotions, mood, and learning, as well
as short and long term memory (Figure 4) (43). Damage to these specific areas from TBI’s could
help explain the various symptoms seen in individuals with CTE.
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Figure 5: This shows general abnormalities caused by CTE. Macro and microscopic
abnormalities between a normal brain (right) and a brain with signs of CTE (right) (46).
Signs and Symptoms of CTE:
Upwards of 90% of TBI’s are classified under what is commonly known as a concussion
and the symptoms associated with these concussions are usually resolved in two weeks or less
(8). Individuals who have suffered mTBI and whose symptoms last longer than three months
may be diagnosed with post concussive syndrome. The symptoms known to be associated with
post concussive syndrome are varying in severity by subject, including memory problems,
irritability and other personality changes, sensitivity to light and noise, sleep disturbances,
depression and other psychological problems, and loss of smell and taste. (9). Multiple
brain injuries, or concussions, can lead to a higher prevalence of post-concussive symptoms and
into the neuropathological disease we know as CTE.
Depression:
Depression is one of the most common symptoms of CTE and is seen more in individuals
who suffer a TBI than in the general population (8). A history of concussion is associated with
3.3-fold greater risk for a diagnosis of depression in adolescents as well as a 2-fold increase in
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the elderly (8). Besides single injury risk, the risk for developing depression is greatly increased
by the number of concussions sustained by an individual. The relative risk of developing
depression increases from 1.5 to 3 when individuals report less than 3 versus 3 or
more concussions (9).
Depression treatment responsiveness is inconsistent the majority of the time, and even
more so for those who suffer from TBI’s (7). A patient having a history of substance abuse,
psychosocial factors, and mood disorders may contribute to the risk of developing depression
following TBI (8). This is why, without a complete understanding of the pathophysiological
mechanism(s) that lead to depression following TBI, targeted disease-modifying therapies
cannot be developed (7). There is no individual mechanism currently identified as the cause of
depression after TBI, but accumulating evidence has shown that inflammatory pathways may
contribute to its development (48). Knowing that inflammation can persist long after TBI, we
can then look at the association between the inflammation caused by the TBI and depression
following (22). A few studies have shown a possible link between increased pro-inflammatory
biomarkers in cerebral spinal fluids (CSF) following a TBI and increased odds of developing
depression (43).
Cytokine Regulation:
Cytokines are a category of signaling proteins that act by binding to specific receptors.
Cytokines can be seen acting on cells that release them via autocrine action, cell to cell signaling
in local tissue via paracrine action, or long distance signaling via endocrine action. Cytokines are
usually produced in a cascade producing other cytokines that can work synergistically or
antagonistically (26). Cytokines are usually linked to the immune system where they are
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released for defense against pathogens. The cytokines focused on here promote inflammation
when released. In a normal body, cytokines are produced in small levels and can increase up to
100 fold more than normal levels when responding to an activating stimulus, such as a
pathogen or, in our case, tissue damage.
There are four ways to measure cytokine changes following TBI: in blood, cerebrospinal
fluid (CSF), microdialysis, and biopsy of brain tissue. Taking measurements from blood is the
least invasive approach by measuring cytokine levels in plasma or serum. In cases of moderate
to severe TBI’s, CSF that would normally be discarded while attempting to lower the intracranial
pressure is saved for biomarker assays. During microdialysis, cerebral probes can be surgically
implanted and measure local levels of cytokines (7).
The majority of studies on cytokine levels following TBI’s has been done with moderate
to severe TBI’s, but recently a study was done on military personal who suffered TBI’s showing
that an elevation in interleukin IL-6 and tumor necrosis factor α (TNFα) in plasma were
associated with post-traumatic stress disorder (PTSD) and depression (28). In this study, 83
participants, who were all deployed the same time span 16 months previously, were given a
Warrior Administered Retrospective Casualty Assessment Tool (WARCAT) and self-reported
PTSD, depression, and quality of life assessments. The WARCAT was used as a self-reporting
tool to assess post deployment and war-related TBI’s. Out of the 83 participants, 20 who selfreported no TBI’s were used as the control and the remaining 63 were used as the TBI group.
PTSD was measured using a PTSD military checklist that scores 0-80 with high scores correlating
to increased severity.

16

Figure 5: Differences in plasma cytokine levels. Significant differences were found in IL-6 and
TNF-α (a and d) but not for IL-10 or IL-6/IL-10 Ratios (b and c). TBI, Traumatic Brain Injury; TNF,
tumor necrosis factor; IL, interleukin (28).
Scores over 50 were identified as being PTSD positive participants. Depression was measured
by using the Quick Inventory of Depressive Symptomatology (QIDS), scoring symptoms from 0
to 7, with higher scores indicating increased severity. Participants with total scores over 13
were considered to have depression (29). More information on the QIDS can be seen in the
supplementary materials. WARCAT scores for the TBI participant group averaged 48.7, whereas
the non-TBI group averaged a lower 32.5. A similar trend was seen with the QIDS scores as well
17

with the TBI group having an average score of 12.4 and the non-TBI average score being 7.7
(28). Plasma samples were then taken from the participants, centrifuged frozen at −80 °C, and
then thawed and analyzed for cytokines as a single batch, results appear in Figure 5.
As Figure 5 shows, IL-6 and TNF-α levels are shown to be significantly elevated in
participants who suffered TBI versus the non-TBI participants. IL-6 and TNF-α are known proinflammatory cytokines and IL-10 is an anti-inflammatory cytokine, as stated earlier the proinflammatory cytokines are associated with increased PTSD and depression symptoms.
Below, in Figure 6, are the levels of cytokines in participants who are a part of the TBI group and
determined to be either low-PTSD and QIDS scores or high-PTSD and QIDS scores. Even within
the TBI participant group, significant differences appear again between IL-6 and TNF-α proinflammatory cytokines being most elevated in the high PTSD and QIDS score group.
These results not only show that TBI relates to elevated pro-inflammatory cytokines, but
also that high levels of pro-inflammatory cytokines relate with elevated PTSD and comorbid
depression (28). Another significant finding of this study is the illustration of elevated cytokine
levels months after the occurrence of TBI, which shows that there can be chronic elevation of
cytokines and inflammation after TBI.
The evidence supporting the inflammatory theory of depression is correlative and relies
of the presence of cytokines elevated in the blood or CSF of depressed individuals compared to
healthy controls (7). A meta-analysis of 82 studies showed that peripheral levels of cytokines
and chemokines, including IL-6 and TNF-α, were elevated in individuals with major depressive
disorders compared to a healthy control (43). Another analysis furthered showed a correlation
between cytokine levels and depression in that they found that cytokine levels decreased after
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the implementation of anti-depression medication (43).

Figure 6: Comparison of cytokine levels in military personnel who suffered TBI’s and have
been diagnosed with low PTSD (N=35) and high PTSD (N=28). Significant differences were
found for IL-6 and TNF-α (a-d) but not for IL-6 or IL-6/IL-10 ratios (b and c) (28).
TBI, Traumatic Brain Injury; TNF, tumor necrosis factor; IL, interleukin.
Also, when interferon cytokines are used as a treatment for hepatitis and multiple sclerosis,
there is a strong association with the development of depression, with up to 80% of patients on
type 1 interferon therapy developing depression (46). Another link between cytokines and
depression is that depression has seemed to be reduced when individuals have been treated
with an anti-cytokine treatment compared to control groups. A review and meta-analysis of 16
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studies showed a major reduction of depression symptoms compared to a placebo (49).
Cytokines play a major role in Cytokines IL-1 and TNF-α directly play a role in
serotonergic signaling (28). They have been shown regulate the serotonin transporter (SERT) by
increasing the production of SERT and recruiting it to the membrane (28). SERT transports
serotonin from the synapse back into the pre-synaptic neuron (10). Serotonin plays an
important role in neuronal circuits, controlling mood and temperament (12). This increase in
SERT leads to the decrease of serotonin in the neuronal synapse, which has been shown to
increase depression (12).
In the hippocampus, TNF-α has significant effects on glutamate signaling by altering the
expression, composition, and phosphorylation of α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid receptor (AMPAR), which effect duration of AMPAR-mediated
spontaneous excitatory postsynaptic currents (8). Glutamate is an excitatory transmitter in the
brain important for memory and learning. TNF-α effects on AMPAR activity appear to be
concentration and exposure length dependent. An example of this is during an acute exogenous
exposure of TNFα when an immediate increase in AMPAR surface expression and activity have
been reported. In contrast, chronic exposure to low levels of TNFα, as in the case of normal
aging, decreases AMPAR’s (8). TNF-α not only has an affect on excitatory neurotransmitters,
but it also affects γ-aminobutyric acid (GABA) receptors. GABA is an inhibitory neurotransmitter
in the brain that prevents stimulation by glutamate; this results in a calming sensation in the
brain. Dysfunction of GABA receptors can play a role in psychiatric disorders and major
depression (22). Specifically, TNFα acting on neurons causes a rapid internalization of GABAAR,
which decreases its inhibitory synaptic strength (Pribiag and Stellwagen, 2013). The effects
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cytokines have on AMPAR and GABA receptors could potentially play a major role in the
depressive symptoms following TBI and as seen in CTE.
Behavioral Changes:
Behavioral changes in patients suffering from CTE are hard to assess and usually are
reported post mortem by relatives of the patient. There have been many reports of this, but
one of the most famous is of American football player Mike Webster. Mike Webster’s battle
against CTE was made into a movie titled Concussion. He was the first individual to be
diagnosed with CTE by Dr. Bennett Omalu in 2002 (38, 39). Family members reported impulsive
aggression, rapid mood swings, and low interest in normal activities. These behaviors seemed
unexplained until after Mike’s death in 2002. Now, and since, these behaviors and more have
been deemed clinical symptoms of CTE.
Although no definite mechanism has been determined for these behavior changes, a
possible explanation could be from the neuronal damage caused P-tau accumulation in mood
controlling areas of the brain. These initial symptoms could be due to damage to the limbic
system resulting in behavioral symptoms, such as emotional lability, aggression, and violence
(13). Other factors could possibly be the accumulation of Lewy bodies in these same areas, as
seen in study mentioned above.
Memory Loss:
Another symptom associated with CTE is memory loss. Temporary memory loss can be
seen in patients instantly following TBI, but usually subsides after a few weeks (9). This can
caused be intense inflammation, brain bleeds, or other damages resulting from the TBI. In CTE,
memory loss is not instantaneous, as in some TBI’s, but slowly progresses over time.
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Figure 7: Comparison of hippocampal pathology in two cases of moderate CTE. In example 1
(a–f), there is a mild hippocampal atrophy, b mild neuronal loss in CA1, c sparse NFTs in CA1 d
sparse NFTs in CA1, AT8 immunostain, e moderate numbers of diffusely immunopo- sitive AT8
stained neurons in CA4, and f occasional AT8 immunopositive NFTs in the dentate gyrus. In
example 2 (g–l), there is g more severe hippocampal atrophy, h clear neuronal loss in CA1, i
moder- ate density of NFTs in CA1, Bielschowsky silver stain, j moderate density of NFTs in CA1,
AT8 immunostain, k high numbers of AT8- stained neurons and NFTs in CA4, and l moderate
numbers of AT8 immunopositive NFTs in the dentate gyrus (40). Bars indicate 100 μm.
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This could possibly be explained by the mechanism of injury and how p-tau propagates through
brain tissues. Location of beginning p-tau formation may be a significant aspect of the slow
onset of symptoms presented by a patient. P-tau in stage one CTE patients is seen accumulated
on the outer cortex of the brain (McKee). As stated above, excessive accumulation of p-tau
causes neuronal dysfunction and death. Knowing that regions of the cerebral cortex are used
for memory and learning, P-tau damage to these areas can cause memory loss. As time
progresses, the P-tau migrates into deeper regions of the brain, causing atrophy to important
memory related structures such as the hippocampus and amygdala. This is why more severe
memory loss can be seen in patients that progress to a higher stage of diagnoses (Figure 7).
As stated in the previous section, glutamate is an important neurotransmitter
associated with memory and learning. Additionally, the number of its receptors, AMPAR, can be
reduced by TNF-α when expressed at chronic low levels (22). As seen in TBI’s, there is a chronic
elevation of cytokines such as TNF- α above basal levels. Potentially, a long term elevation of
TNF-α could be one reason why individuals with CTE have problems with memory and learning.
Further, with CTE being a comorbid disease, other diseases such as Lewy body disease and
Alzheimer’s disease could play a role in the degradation of memory. As seen above, Lewy
Bodies are a possible source of the dementia symptoms demonstrated by CTE-LBD patients.
Diagnosis:
Diagnosis of CTE so far has only been done post mortem in patients. The standard scale
for the diagnosis of CTE was proposed in 2013 and staged CTE I through IV, with IV being most
severe. In 2013, the neuro-pathological diagnosis of CTE were proposed, as follows:
1. Perivascular foci of p-tau immunoreactive NFTs and ATs in the neocortex
23

2. Irregular distribution of p-tau immunoreactive NFTs and ATs at the depths of cerebral
sulci
3. NFTs in the cerebral cortex located preferentially in the superficial layers (often most
pronounced in tem- portal cortex)
4. Supportive, non-diagnostic features: Clusters of sub-pial ATs in the cerebral cortex, most
pronounced at the sulcal depths. (3)
Abbreviations: NFTs =Neurofibrillary tangles, ATs = astrocytic Tangles
A study performed in March 2013 determined that the diagnostic neuropathological lesion of
Chronic Traumatic Encephalopathy (CTE) was different from other taupathies. The
pathognomonic lesion of CTE consists of p-tau aggregates in neurons, astrocytes, and cell
processes around small vessels in an irregular pattern at the depths of the cortical sulci (Figure
8) (3).

Figure 8: Low magnification of phosphorylated tau (p-tau) stained slides showing the spatial
pattern in CTE pathology in cortical sulci. Three different cerebral cortex slides from 3 separate
CTE cases. The darker brown regions are areas of stained p-tau proteins (3).
It was also determined that the p-tau was detectible at a lower power than other
24

tauapathies and in an irregular pattern (3). This pattern consisted of astrocytic tangles, dot and
thread like neurites located in the depths of sulci and along penetrating blood vessels. This
study also discovered that CTE wasn’t a single diagnosis, but is considered a co-morbid disease.
Staging diagnosis for CTE was based of work from Braak and Braak who determined that there
are 6 different stages based on characteristic distribution of NFT in patients who have AD. This
staging system is the base of diagnosing AD used by the Nation Institute on Aging (3). The
diagnostic stages of CTE are:
I: Brains that are in stage I show no gross anatomic or macroscopic differences
compared to normal brains. Microscopically, they show small isolated perivascular focal
epicenters of p-tau NFTs and neuropil neurites. These NFTs and neuropil neurites are
characterized as dot and thread like. Tau pathology is most commonly localized to the
depths of the cerebral sulci of the frontal, temporal, insular, septal and parietal cortices,
although there may also be sparse NFT scattered throughout the adjacent cortex.
II: Subtle macroscopic changes within the brain may occur in Stage II. This could be mild
enlargement of the frontal horns of the lateral ventricles and third ventricle; cavum
septum pellucidum and the locus coeruleus and substantia nigra may also become pale.
Multiple epicenters of p-tau will be found in the cortices and AT are seen in sub-pial
regions. In cortexes adjacent to p-tau epicenters, NFT are seen throughout cerebral
layers.
III: The majority of brains in stage III have macroscopic changes but little anatomical
change. Usually, there is a reduction in brain weight, mild atrophy of the temporal and
frontal lobes, and enlargement of the lateral and third ventricles. Also, atrophy is seen in
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the mammillary bodies, thalamus, and hypothalamus, as well as the corpus callosum
becoming thin. Half of subjects have septal abnormalities. The cavum septum
pellucidum and locus coeruleus become pale. Microscopically, patches of merging NFT,
NT’s, and AT are found around blood vessels in sulcal depths and in superficial laminae
of the cortex. NFT can be seen in the olfactory bulb, hippocampus, entorhinal cortex,
amygdala, hypothalamus, mammillary bodies, nucleus basalis of Meynert, substantia
nigra, dorsal and median raphe nuclei, and locus coeruleus. Neurofibrillary degeneration
of the hippocampus can be seen.
IV: Stage IV CTE brains show substantial decrease in brain weight with pronounced
atrophy of cerebrum, frontal and temporal lobes, medial temporal lobes, mammillary
bodies, and thalamus. Wide spread atrophy of white matter can be seen. Thinning of
corpus callosum and hypothalamic floor are common. Septum abnormalities can be
seen, including cavum septum, perforations, fenestrations or total absence of the
posterior septum. The cavum septum pellucidum and locus coeruleus are pale.
Microscopically, diffuse myelin loss, astrocytosis of the white matter, and neuronal loss
in the cerebral cortex, hippocampus and substantia nigra occur. P-tau pathology is
densely distributed throughout the cerebrum, thalamus, hypothalamus, mammillary
bodies, basal ganglia, brainstem, cerebellar dentate nucleus, and, occasionally, spinal
cord. The visual cortex is usually a spared area in this disease. NFT, most of which are
extracellular, are found throughout the hippocampal formation, including the dentate
gyrus. Severe neuronal occurs loss in the hippocampus. There is marked loss of
myelinated nerve fibers, axonal dystrophy and loss throughout the cerebral and
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cerebellar white matter.

Stage one (I) CTE

Stage Four (IV) CTE
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Figure 9: Comparison of stage I CTE to stage IV CTE. Stage I shows small p-tau (brown spots)
forming in the cortical sulci. Stage IV illustrates widespread severe p-tau pathology, affecting
most regions of the cerebral cortex and the medial temporal lobe but sparing the visual cortex
in all but the most severe cases (40).
Treatment:
With diagnosis of CTE being done post mortem, there is no definitive treatment at this
time. Preventative measures while participating in contact sports or military related events can
help avoid TBI’s. Wearing the correct protective equipment and avoiding unnecessary collisions
or concussive blasts is the best way to avoid TBI’s. Also, athletes and military personnel should
follow their organizations’ concussion protocols after experiencing a TBI to prevent further
damage. Treatment of symptoms of CTE may be done to help improve quality of life of the
patient. Studies have considered lowering depression symptoms by attempting to lower proinflammatory cytokines in patients following a TBI. Blocking these signals could prevent
inflammation and excitatory damage to neurons caused by the dysregulation of the glutamate
and GABA signaling (7). Treatments with cytokine inhibitors has been shown to promote
functional recovery in learning and memory tasks in TBI mouse models when implemented one
week after sustaining the injury (35). Experiments have also shown that, following a TBI, neuro
stem cells (NSC) may help in a regenerative process of the brain (35). This has sparked the
interest of researchers to see if stem cell implementation could possibly be used as treatment
method. Two methods of stem cell treatment are currently being investigated. The first is the
modulation of naturally occurring endogenous NSC reservoirs within the patient and the second
is implanting exogenous NSC into the patient to assist regeneration (35). Both methods have
shown positive results in treatment of TBI’s in animal models but the human neurogenesis
process is still unclear. A potential issue with this treatment process is that areas where a TBI
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occurred may be to severely damaged and too hostile for the transplanted NSC to survive (35).
Further, generation of sufficient functional NSC to be implanted has been proven difficult to do.
Treatments adding Omega-3 fatty acids to a person’s diet has also shown to help combat TBI
symptoms (50). Omega-3 fatty acids have been shown to help with neuro-synaptic transmission
and improving neuroplasticity. Other possible treatments like behavioral therapy and memory
exercises can also help deal with symptomatic mood swings and difficulty with recall.
Conclusion:
Limitations:
With the brain being encased in the skull, it is difficult to study without its removal. This
is the most significant limitation encountered while researching CTE; it limits the number of
participants available for studies. Additionally, with CTE only being heavily researched in recent
years, little information of the living history of the patients used in most of these studies exists.
Knowledge of the p-tau mechanism also remains incomplete, which makes it difficult when
trying to create a treatment to inhibit its toxicity. The majority of the studies that have shown
cytokine changes in individuals following TBI have been done in patients who have suffered a
moderate to severe TBI. There has been limited data from individuals who suffer from mild TBI.
Further, few studies have been done longitudinally for cytokine biomarkers within the blood or
CSF. Knowing how long cytokines last and when possible increase may occur in the body could
help prevent chronic inflammation in the brain.
Future Research:
Future research in this field could occur in a wide range of areas. The most demanding
areas of concern would be diagnosis of CTE in patients who are still living. A current study,
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started in 2014, named Understanding Neurological Injuries and Traumatic Encephalopathy
(UNITE), is working towards this. Their goal is to find associations in living patients at risk of CTE
that can be then confirmed postmortem. Their hope is that this information could be used for
further clinical diagnoses of CTE. Also, there are studies trying to solve this issue by tagging the
p-tau protein with a marker that can be seen by Positron emissions testing (PET) scans. These
studies hope that early diagnoses of the disease can be achieved through observing the
accumulation and binding patterns of these P-tau proteins. Currently, the mechanism of neuro
toxic p-tau is little understood. Further research needs to be done in order to understand the
full pathogenesis of the toxic proteins and ways to prevent its propagation in CTE. Another
future field of experiments is looking at biomarkers such as elevated levels of P-tau and
cytokines in CSF. This information could also be used to help in early diagnosis. Over the past
decade, a lot of information and associations have been discovered involving this disease, but
funding and future discoveries are needed in hopes of finding a cure.
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